Related Experiment Video
Updated: Aug 18, 2026
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during
Harald Dobnig1, Adrien Sipos, Yebin Jiang
1Department of Internal Medicine, Division of Endocrinology, Medical University, Auenbruggerplatz 15, A-8036 Graz, Austria. harald.dobnig@meduni-graz.at
Context:
Biochemical markers of bone turnover may reflect bone structure during anabolic treatment.
Objective:
The objective was to evaluate associations between changes in biochemical markers and structural and dynamic bone parameters during teriparatide treatment.
Design:
This study was a randomized, multicenter, double-blind, placebo-controlled fracture prevention trial, with 20-month median treatment duration for biopsy subset.
Setting:
The trial was conducted at 11 clinical study sites.
Patients:
Sixty-one postmenopausal women with osteoporosis who had paired transiliac biopsy specimens participated in the study.
Interventions:
Once-daily sc injections of either placebo or teriparatide (20 or 40 microg) were administered.
Main Outcome Measures:
The study measured: 1) serum and urinary biochemical markers of bone formation [bone alkaline phosphatase and procollagen I C-terminal propeptide (PICP)] and resorption (N-telopeptide and deoxypyridinoline); and 2) structural and dynamic analyses of bone biopsies, including two-dimensional (2D) histomorphometry and three-dimensional (3D) micro-computed tomography evaluations measured at baseline (n = 57) and 12 (n = 21) or 22 (n = 36) months.
Results:
U-N-telopeptide/creatinine and serum-PICP correlated with bone structure and dynamic indices at baseline, respectively. Changes in bone alkaline phosphatase at 1 month correlated with changes at 22 months in 2D wall thickness (r = 0.73; P = 0.001), trabecular bone volume (trabecular bone volume per total volume, BV/TV) (r = 0.58; P < 0.05), marrow star volume (r = -0.51; P = 0.05); 3D trabecular thickness (r = 0.49; P < 0.05), and BV/TV (r = 0.54; P < 0.05). Changes in PICP at 1 month correlated with changes in wall thickness (r = 0.60; P = 0.01), and 2D BV/TV (r = 0.51; P < 0.05) at 22 months. Changes in markers at 6 or 12 months were not associated with changes in structural or dynamic parameters.
Conclusions:
Early (1-month) changes in biochemical markers of bone formation, but not resorption, correlated with improvements in bone structure after 22 months of teriparatide therapy.
Related Concept Videos
01:40Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:31Osteoclasts in Bone Remodeling